Focused On-demand Library for Vascular endothelial growth factor receptor 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Fetal liver kinase 1; Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1

Alternative UPACC:

P35968; A2RRS0; B5A925; C5IFA0; O60723; Q14178


Vascular endothelial growth factor receptor 2 (VEGFR-2), also known as Kinase insert domain receptor (KDR), plays a pivotal role in vascular development and angiogenesis. It acts as a cell-surface receptor for VEGFA, VEGFC, and VEGFD, promoting endothelial cell proliferation, survival, migration, and differentiation. VEGFR-2 activation triggers multiple signaling pathways, including MAPK, AKT1, and PLCG1, essential for vascular permeability and embryonic hematopoiesis.

Therapeutic significance:

VEGFR-2 is linked to capillary infantile hemangioma, a condition marked by localized growth of capillary endothelium. Understanding VEGFR-2's role could lead to innovative treatments for angiogenesis-related diseases, offering hope for conditions characterized by abnormal blood vessel growth.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.